Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BDTX NASDAQ:DRRX NASDAQ:ENTA NASDAQ:HRTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBDTXBlack Diamond Therapeutics$4.01-4.1%$3.26$1.20▼$4.45$228.33M3.071.11 million shs869,270 shsDRRXDURECT$1.91$1.91$0.48▼$2.64$59.31M0.92699,433 shsN/AENTAEnanta Pharmaceuticals$11.01-3.3%$9.14$4.09▼$15.34$235.39M0.891.58 million shs325,530 shsHRTXHeron Therapeutics$1.29-0.8%$1.30$1.04▼$2.68$236.47M1.251.47 million shs638,534 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBDTXBlack Diamond Therapeutics0.00%-1.96%+22.26%+27.30%+21.15%DRRXDURECT0.00%0.00%0.00%+238.05%+44.70%ENTAEnanta Pharmaceuticals0.00%-0.09%+44.11%+42.43%-12.83%HRTXHeron Therapeutics0.00%+0.78%+4.88%-32.81%-26.70%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBDTXBlack Diamond Therapeutics$4.01-4.1%$3.26$1.20▼$4.45$228.33M3.071.11 million shs869,270 shsDRRXDURECT$1.91$1.91$0.48▼$2.64$59.31M0.92699,433 shsN/AENTAEnanta Pharmaceuticals$11.01-3.3%$9.14$4.09▼$15.34$235.39M0.891.58 million shs325,530 shsHRTXHeron Therapeutics$1.29-0.8%$1.30$1.04▼$2.68$236.47M1.251.47 million shs638,534 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBDTXBlack Diamond Therapeutics0.00%-1.96%+22.26%+27.30%+21.15%DRRXDURECT0.00%0.00%0.00%+238.05%+44.70%ENTAEnanta Pharmaceuticals0.00%-0.09%+44.11%+42.43%-12.83%HRTXHeron Therapeutics0.00%+0.78%+4.88%-32.81%-26.70%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBDTXBlack Diamond Therapeutics 2.57Moderate Buy$9.60139.40% UpsideDRRXDURECT 2.00HoldN/AN/AENTAEnanta Pharmaceuticals 2.71Moderate Buy$20.8389.22% UpsideHRTXHeron Therapeutics 2.25Hold$4.50248.84% UpsideCurrent Analyst Ratings BreakdownLatest DRRX, ENTA, HRTX, and BDTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/15/2025BDTXBlack Diamond TherapeuticsStifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$8.0010/10/2025BDTXBlack Diamond TherapeuticsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold10/8/2025BDTXBlack Diamond TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)10/8/2025ENTAEnanta PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025HRTXHeron TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/7/2025HRTXHeron TherapeuticsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold10/1/2025ENTAEnanta PharmaceuticalsJefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Buy$14.00 ➝ $20.009/30/2025ENTAEnanta PharmaceuticalsWestpark CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$24.00 ➝ $28.009/27/2025BDTXBlack Diamond TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)9/27/2025ENTAEnanta PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025HRTXHeron TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 10/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBDTXBlack Diamond TherapeuticsN/AN/AN/AN/A$1.47 per shareN/ADRRXDURECT$1.66M35.80N/AN/A$0.29 per share6.59ENTAEnanta Pharmaceuticals$67.64M3.48N/AN/A$6.08 per share1.81HRTXHeron Therapeutics$144.29M1.64N/AN/A($0.22) per share-5.86Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBDTXBlack Diamond Therapeutics-$69.68M$0.2317.44N/AN/AN/A12.70%9.58%11/4/2025 (Estimated)DRRXDURECT-$8.32M-$0.10N/AN/AN/A-96.19%-259.16%-71.78%11/12/2025 (Estimated)ENTAEnanta Pharmaceuticals-$116.04M-$4.32N/AN/AN/A-141.98%-89.02%-27.28%12/1/2025 (Estimated)HRTXHeron Therapeutics-$13.58M-$0.02N/AN/AN/A-0.62%N/A-0.40%11/11/2025 (Estimated)Latest DRRX, ENTA, HRTX, and BDTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/11/2025Q3 2025HRTXHeron Therapeutics-$0.02N/AN/AN/A$39.03 millionN/A11/4/2025Q3 2025BDTXBlack Diamond Therapeutics-$0.23N/AN/AN/AN/AN/A8/12/2025Q2 2025DRRXDURECT-$0.13-$0.07+$0.06-$0.07$0.32 million$0.45 million8/11/2025Q3 2025ENTAEnanta Pharmaceuticals-$1.25-$0.85+$0.40-$0.85$16.21 million$18.31 million8/8/2025Q2 2025HRTXHeron Therapeutics-$0.01-$0.02-$0.01-$0.02$38.08 million$37.20 million8/7/2025Q2 2025BDTXBlack Diamond Therapeutics-$0.25-$0.19+$0.06-$0.19N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBDTXBlack Diamond TherapeuticsN/AN/AN/AN/AN/ADRRXDURECTN/AN/AN/AN/AN/AENTAEnanta PharmaceuticalsN/AN/AN/AN/AN/AHRTXHeron TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBDTXBlack Diamond TherapeuticsN/A8.738.73DRRXDURECTN/A0.980.95ENTAEnanta PharmaceuticalsN/A5.005.00HRTXHeron TherapeuticsN/A0.820.53Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBDTXBlack Diamond Therapeutics95.47%DRRXDURECT28.03%ENTAEnanta Pharmaceuticals94.99%HRTXHeron Therapeutics80.01%Insider OwnershipCompanyInsider OwnershipBDTXBlack Diamond Therapeutics5.97%DRRXDURECT3.20%ENTAEnanta Pharmaceuticals13.89%HRTXHeron Therapeutics5.86%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBDTXBlack Diamond Therapeutics9056.94 million53.54 millionOptionableDRRXDURECT8031.05 million30.06 millionOptionableENTAEnanta Pharmaceuticals16021.38 million18.41 millionOptionableHRTXHeron Therapeutics300183.31 million172.57 millionOptionableDRRX, ENTA, HRTX, and BDTX HeadlinesRecent News About These CompaniesAIGH Capital Management LLC Purchases 231,057 Shares of Heron Therapeutics, Inc. $HRTXOctober 20 at 3:04 AM | marketbeat.comCyndeo Wealth Partners LLC Takes Position in Heron Therapeutics, Inc. $HRTXOctober 12, 2025 | marketbeat.comHeron Therapeutics (NASDAQ:HRTX) Stock Rating Upgraded by Zacks ResearchOctober 10, 2025 | marketbeat.comHeron Therapeutics (NASDAQ:HRTX) Earns "Sell (E+)" Rating from Weiss RatingsOctober 9, 2025 | marketbeat.comCongress Park Capital LLC Has $4.70 Million Stake in Heron Therapeutics, Inc. $HRTXSeptember 21, 2025 | marketbeat.comHeron Therapeutics files $125M mixed securities shelfSeptember 9, 2025 | msn.comHeron Therapeutics files to sell 37.91M shares of common stock for holdersSeptember 9, 2025 | msn.comHeron Therapeutics Signs New Headquarters LeaseAugust 28, 2025 | tipranks.comHeron Therapeutics: The View From 30,000 Feet Amid The Zynrelef LaunchAugust 25, 2025 | seekingalpha.comHeron Therapeutics adopts tax benefits preservation planAugust 16, 2025 | msn.comHeron Therapeutics, Inc. Adopts Tax Benefits Preservation Plan to Protect NOL Assets and Shareholder ValueAugust 15, 2025 | prnewswire.comHeron Therapeutics, Inc. (NASDAQ:HRTX) Director Buys $2,649,819.00 in StockAugust 13, 2025 | insidertrades.comHeron Therapeutics Signs Agreement with PatheonAugust 12, 2025 | msn.comHeron Therapeutics Announces Strategic Financial InitiativesAugust 12, 2025 | theglobeandmail.comRubric capital buys Heron Therapeutics (HRTX) shares worth $3.5mAugust 12, 2025 | investing.comHeron Therapeutics, Inc. (NASDAQ:HRTX) Q2 2025 Earnings Call TranscriptAugust 12, 2025 | msn.comHeron Therapeutics, Inc.: Heron Therapeutics Announces Comprehensive Capital Restructuring to Support Growth and Extend Maturity ProfileAugust 8, 2025 | finanznachrichten.deHeron (HRTX) Q2 Acute Care Jumps 56%August 8, 2025 | aol.comAHeron Therapeutics, Inc. (HRTX) Q2 2025 Earnings Call TranscriptAugust 8, 2025 | seekingalpha.comHeron Therapeutics (HRTX) Q2 Earnings: Taking a Look at Key Metrics Versus EstimatesAugust 8, 2025 | zacks.comHeron Therapeutics (HRTX) Reports Q2 Loss, Misses Revenue EstimatesAugust 8, 2025 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesDatavault AI: The New AI Contender Backed by Big FundingBy Jeffrey Neal Johnson | October 1, 2025Qualcomm’s RSI Just Hit Its High of the Year—Why That’s BullishBy Sam Quirke | September 24, 2025Rivian Is Emerging as a Supplemental Tesla PlayBy Jordan Chussler | September 26, 2025Fundamentals Say Bet Against the Recent Adobe Downgrade By Gabriel Osorio-Mazilli | September 30, 2025Is Tilray's Stock Price Surge a Pipe Dream of Political Hype?By Jeffrey Neal Johnson | October 1, 2025DRRX, ENTA, HRTX, and BDTX Company DescriptionsBlack Diamond Therapeutics NASDAQ:BDTX$4.01 -0.17 (-4.07%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$4.06 +0.04 (+1.12%) As of 08:02 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Black Diamond Therapeutics, Inc., a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.DURECT NASDAQ:DRRXDURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. It also offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine over three days in adults; and Methydur to treat attention deficit hyperactivity disorder. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in other countries. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; and Innocoll Pharmaceuticals Limited. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.Enanta Pharmaceuticals NASDAQ:ENTA$11.01 -0.37 (-3.25%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$11.22 +0.22 (+1.95%) As of 08:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.Heron Therapeutics NASDAQ:HRTX$1.29 -0.01 (-0.77%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$1.30 +0.01 (+0.78%) As of 08:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Broadcom Inks OpenAI Deal: Why It's A Huge Win for AVGO Stock Institutions Are Fueling CrowdStrike’s Next Leg Higher This AI Chip Giant Could Be the Market’s Next Big Winner JPMorgan Crushes Q3; But Is the Steady Eddy Stock Hitting A Wall? Microsoft & NVIDIA Unveil GB300 Supercomputer as AI Race Heats Up This Less-Hyped Tech Stock Could Be the Key to the Next AI Wave Archer Buys Rival's Patent Treasure Trove in Strategic Move Prologis Stock Surges: Why the Rally May Continue Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
